A Decision Point Between Transdifferentiation and Programmed Cell Death Priming Controls KRAS-dependent Pancreatic Cancer Development

KRAS-dependent acinar-to-ductal metaplasia (ADM) is a fundamental step in the development of pancreatic ductal adenocarcinoma (PDAC), but the involvement of cell death pathways remains unclear. Here, we show that key regulators of programmed cell death (PCD) become upregulated during KRAS-driven ADM, thereby priming transdifferentiated cells to death. Using transgenic mice and primary cell and organoid cultures, we show that transforming growth factor (TGF)-β-activated kinase 1 (TAK1), a kinase regulating cell survival and inflammatory pathways, prevents the elimination of transdifferentiated cells through receptor-interacting protein kinase 1 (RIPK1)-mediated apoptosis and necroptosis, enabling PDAC development. Accordingly, pharmacological inhibition of TAK1 induces PCD in patient-derived PDAC organoids. Importantly, cell death induction via TAK1 inhibition does not appear to elicit an overt injury-associated inflammatory response. Collectively, these findings suggest that TAK1 supports cellular plasticity by suppressing spontaneous PCD activation during ADM, representing a promising pharmacological target for the prevention and treatment of PDAC.

References

Principe D, Underwood P, Korc M, Trevino J, Munshi H, Rana A . The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy. Front Oncol. 2021; 11:688377. PMC: 8319847. DOI: 10.3389/fonc.2021.688377. View

Mahadevan K, McAndrews K, LeBleu V, Yang S, Lyu H, Li B . KRAS inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8 T cells. Cancer Cell. 2023; 41(9):1606-1620.e8. PMC: 10785700. DOI: 10.1016/j.ccell.2023.07.002. View

Hingorani S, Petricoin E, Maitra A, Rajapakse V, King C, Jacobetz M . Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2004; 4(6):437-50. DOI: 10.1016/s1535-6108(03)00309-x. View

van de Wiel M, van Wieringen W . CGHregions: dimension reduction for array CGH data with minimal information loss. Cancer Inform. 2009; 3:55-63. PMC: 2675846. View

Halbrook C, Lyssiotis C, Pasca di Magliano M, Maitra A . Pancreatic cancer: Advances and challenges. Cell. 2023; 186(8):1729-1754. PMC: 10182830. DOI: 10.1016/j.cell.2023.02.014. View

Ying H, Dey P, Yao W, Kimmelman A, Draetta G, Maitra A . Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2016; 30(4):355-85. PMC: 4762423. DOI: 10.1101/gad.275776.115. View

Bettermann K, Vucur M, Haybaeck J, Koppe C, Janssen J, Heymann F . TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. Cancer Cell. 2010; 17(5):481-96. DOI: 10.1016/j.ccr.2010.03.021. View

Krishna-Subramanian S, Singer S, Armaka M, Banales J, Holzer K, Schirmacher P . RIPK1 and death receptor signaling drive biliary damage and early liver tumorigenesis in mice with chronic hepatobiliary injury. Cell Death Differ. 2019; 26(12):2710-2726. PMC: 6861136. DOI: 10.1038/s41418-019-0330-9. View

Kanayama A, Seth R, Sun L, Ea C, Hong M, Shaito A . TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains. Mol Cell. 2004; 15(4):535-48. DOI: 10.1016/j.molcel.2004.08.008. View

10.

Linnemann J, Miura H, Meixner L, Irmler M, Kloos U, Hirschi B . Quantification of regenerative potential in primary human mammary epithelial cells. Development. 2015; 142(18):3239-51. PMC: 4582177. DOI: 10.1242/dev.123554. View

11.

Mukhopadhyay H, Lee N . Multifaceted roles of TAK1 signaling in cancer. Oncogene. 2019; 39(7):1402-1413. PMC: 7023988. DOI: 10.1038/s41388-019-1088-8. View

12.

Dai E, Han L, Liu J, Xie Y, Zeh H, Kang R . Ferroptotic damage promotes pancreatic tumorigenesis through a TMEM173/STING-dependent DNA sensor pathway. Nat Commun. 2020; 11(1):6339. PMC: 7732843. DOI: 10.1038/s41467-020-20154-8. View

13.

Wang X, Allen S, Blake J, Bowcut V, Briere D, Calinisan A . Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS Inhibitor. J Med Chem. 2021; 65(4):3123-3133. DOI: 10.1021/acs.jmedchem.1c01688. View

14.

Meerbrey K, Hu G, Kessler J, Roarty K, Li M, Fang J . The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. Proc Natl Acad Sci U S A. 2011; 108(9):3665-70. PMC: 3048138. DOI: 10.1073/pnas.1019736108. View

15.

Luedde T, Schwabe R . NF-κB in the liver--linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2011; 8(2):108-18. PMC: 3295539. DOI: 10.1038/nrgastro.2010.213. View

16.

Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov J . GenePattern 2.0. Nat Genet. 2006; 38(5):500-1. DOI: 10.1038/ng0506-500. View

17.

Crouchet E, Bandiera S, Fujiwara N, Li S, El Saghire H, Fernandez-Vaquero M . A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery. Nat Commun. 2021; 12(1):5525. PMC: 8448834. DOI: 10.1038/s41467-021-25468-9. View

18.

Kawaguchi Y, Cooper B, Gannon M, Ray M, MacDonald R, Wright C . The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors. Nat Genet. 2002; 32(1):128-34. DOI: 10.1038/ng959. View

19.

Peck D, Crawford E, Ross K, Stegmaier K, Golub T, Lamb J . A method for high-throughput gene expression signature analysis. Genome Biol. 2006; 7(7):R61. PMC: 1779561. DOI: 10.1186/gb-2006-7-7-r61. View

20.

Sato S, Sanjo H, Takeda K, Ninomiya-Tsuji J, Yamamoto M, Kawai T . Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol. 2005; 6(11):1087-95. DOI: 10.1038/ni1255. View